Farmaindustria proposes twelve measures to improve access to new treatments for patients with rare diseases

Improving access to new treatments for Spanish patients with rare diseases is an ever pressing issue. For this reason, Farmaindustria has launched Propuestas para la mejora del acceso de los pacientes a los medicamentos huérfanos. This new document proposes 12 specific measures to ensure that Spanish patients with rare diseases have the maximum amount of opportunities available for treatment, in line with those of other European countries. Already in 2022, the pharmaceutical industry proposed about twenty measures to improve access to new drugs.

“Patients with rare diseases cannot wait to have all the evidence to finance a medicine that already has a European authorization with a favorable benefit-risk balance,” says the director of Farmaindustria’s Access Department, Isabel Pineros. “The pharmaceutical industry is willing to take some of the risk involved in evaluating and financing orphan drugs. It is time to assume that these drugs cannot be tested as those indicated for frequent pathologies ”, she adds.

To speed up the arrival of these drugs the industry has proposed that an early dialogue be established with the Administration once the drug has received a favorable report from the EMA. It is then crucial to speed up procedures so that the evaluation and financing do not exceed three months and the therapeutic positioning reports do not exceed 60 days.

SOURCE: Farmaindustria